Sweeney C, Martin AJ, Zielinski RR, et al. Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. ASCO Annual Meeting 2019, abstract LBA2.
20-jaars risico op terugkeer borstkanker na hormonale therapie
nov 2017 | Borstkanker